Author

A. Chinnaiyan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Parolia· 2 shared B. Mullan· 1 shared C. C. Collins· 1 shared C. Hawkins· 1 shared C. J. Ong· 1 shared C. Koschmann· 1 shared C. Thomas· 1 shared D. Lin· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Parolia

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Deciphering the Transcription Factor Landscape in Neuroendocrine Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation

Y. Wang, H. Xue, X. Zhu, D. Lin, X. Dong, Z. Chen, J. Chen, M. Shi, Y. Ni, J. Cao, R. Wu, N. Kang, X. Pang, F. Crea, Y.-Y. Lin, , Y. Wang

This study identifies lineage-specific transcription factor profiles in prostate cancer progression, revealing dynamic shifts during NE transdifferentiation and proposing a three-phase model.

bioRxiv · Apr 27, 2024Cancer Biology

Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors

M. B. Mumphrey, N. Hosseini, A. Parolia, J. Geng, W. Zou, M. Raghavan, A. Chinnaiyan, M. Cieslik

The paper identifies distinct mutational processes in MHC class I and II genes across primary and metastatic tumors, showing positive selection for mutations disrupting immune interfaces and linking them to immune checkpoint inhibitor response.

bioRxiv · Jan 22, 2023Cancer Biology

Therapeutic reversal of prenatal pontine ID1 signaling in DIPG

V. N. Yadav, M. K. Harris, D. Messinger, C. Thomas, J. R. Cummings, T. Yang, R. Woo, R. Siddaway, M. Burkert, S. Stallard, T. Qin, B. Mullan, R. Siada, R. Ravindran, M. Niculcea, , C. Koschmann

This study identifies ID1 upregulation in DIPG tumor cells and shows that CBD can reduce ID1-driven invasiveness in vitro and in vivo.

bioRxiv · May 10, 2021 · PreprintCancer Biology